Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2018 07:26 ET | Source: Ablynx NV

ABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK FUNDAMENTALLY UNDERVALUES THE COMPANY AND ITS FUTURE PROSPECTS

FOR IMMEDIATE RELEASE REGULATED INFORMATION - INSIDE INFORMATION GHENT, Belgium, 8 January 2018 - Ablynx NV (Euronext Brussels and Nasdaq: ABLX) ("Ablynx" or the "Company") today confirmed...
January 04, 2018 01:01 ET | Source: Ablynx NV

ABLYNX TO PRESENT AT THE 36th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

GHENT, Belgium, 4 January 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday 8 January 2018 at...
January 04, 2018 01:01 ET | Source: Ablynx NV

ABLYNX PRESENTEERT TIJDENS DE 36e JAARLIJKSE J.P. MORGAN HEALTHCARE CONFERENTIE

GENT, België, 4 januari 2018 - Ablynx [Euronext Brussels en Nasdaq: ABLX] zal een presentatie geven tijdens de 36e Jaarlijkse J.P. Morgan Healthcare Conferentie op maandag 8 januari 2018 om 9u30...
December 27, 2017 01:01 ET | Source: Ablynx NV

KENNISGEVING MET BETREKKING TOT OPHEFFING LOCK-UP RESTRICTIE

GEREGLEMENTEERDE INFORMATIE GENT, België, 27 december 2017 - Ablynx NV [Euronext Brussels en Nasdaq: ABLX], maakte vandaag bekend dat Merrill Lynch, Pierce, Fenner & Smith...
December 27, 2017 01:01 ET | Source: Ablynx NV

NOTICE IN RELATION TO WAIVER OF LOCK-UP RESTRICTION

REGULATED INFORMATION GHENT, Belgium, 27 December 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that Merrill Lynch, Pierce, Fenner & Smith Incorporated, J.P. Morgan...
December 21, 2017 01:01 ET | Source: Ablynx NV

ABLYNX ANNOUNCES POSITIVE DATA FROM ITS JAPANESE ETHNO-BRIDGING STUDY OF CAPLACIZUMAB

Comparable pharmacokinetics (PK) observed in Japanese and Caucasian healthy volunteers Caplacizumab was well-tolerated in all groups GHENT, Belgium, 21 December 2017 - Ablynx NV [Euronext...
December 21, 2017 01:01 ET | Source: Ablynx NV

ABLYNX DEELT POSITIEVE DATA MEE VOOR HAAR JAPANSE ETNO-BRIDGING STUDIE MET CAPLACIZUMAB

Vergelijkbare farmacokinetiek (PK) waargenomen in Japanse en Kaukasische vrijwilligers Caplacizumab werd goed verdragen in alle groepen GENT, België, 21 december 2017 - Ablynx NV [Euronext...
December 12, 2017 07:41 ET | Source: Ablynx NV

ABLYNX REPORTS ADDITIONAL CLINICALLY IMPORTANT BENEFITS OF CAPLACIZUMAB FROM ITS PHASE III HERCULES STUDY IN ACQUIRED TTP

Additional results from the Phase III HERCULES study showed that treatment with caplacizumab resulted in: 38% relative reduction in the number of days of plasma exchange (PEX) 41% relative...
December 12, 2017 07:41 ET | Source: Ablynx NV

ABLYNX RAPPORTEERT BIJKOMENDE KLINISCH BELANGRIJKE VOORDELEN VAN CAPLACIZUMAB VAN HAAR FASE III HERCULES STUDIE IN VERWORVEN TTP

Bijkomende resultaten van de Fase III HERCULES studie toonden aan dat behandeling met caplacizumab resulteerde in: 38% relatieve vermindering in het aantal dagen plasmaferese (PEX) 41% relatieve...
December 07, 2017 01:01 ET | Source: Ablynx NV

ABLYNX WILL HOST A WEBCAST TO DISCUSS ADDITIONAL DATA FROM ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB IN ACQUIRED TTP FOLLOWING ASH LATE-BREAKING DATA PRESENTATION

GHENT, Belgium, 7 December 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX] announced today that the Ablynx management team will host a conference call and webcast to present additional data from...